Hitoshi Hagita

Discovery of Tofogliflozin, a Novel <i>C</i>-Arylglucoside with an <i>O</i>-Spiroketal Ring System, as a Highly Selective Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

Yoshihito Ohtake, Tsutomu Sato, Takamitsu Kobayashi et al. · Journal of Medicinal Chemistry · 2012 · 168 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Tofogliflozin, a Potent and Highly Specific Sodium/Glucose Cotransporter 2 Inhibitor, Improves Glycemic Control in Diabetic Rats and Mice

Masayuki Suzuki, Kiyofumi Honda, Masanori Fukazawa et al. · Journal of Pharmacology and Experimental Therapeutics · 2012 · 166 citations

Medicine, Pharmacology, Pharmacotherapy +17

EOS789, a novel pan-phosphate transporter inhibitor, is effective for the treatment of chronic kidney disease–mineral bone disorder

Yoshinori Tsuboi, Shuichi Ohtomo, Yasuhiro Ichida et al. · Kidney International · 2020 · 42 citations

Medicine, Endocrinology, Pharmacology +17

<i>In vitro</i>profiling of the metabolism and drug–drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP

Mizuki Yamane, Kosuke Kawashima, Koji Yamaguchi et al. · Xenobiotica · 2014 · 24 citations

Medicine, Pharmacokinetics, Pharmacology +17

Fluorescent cytochemical detection of sialidase activity using 5-bromo-4-chloroindol-3-yl-α-D-N-acetylneuraminic acid as the substrate

Hitoshi Hagita, Yoshiharu Iwabuchi, Ikuo Fujii et al. · Histochemistry and Cell Biology · 2002 · 24 citations

Life Sciences, Biochemistry, Molecular Biology +8